Review



3160004b  (fluidigm)


Bioz Verified Symbol fluidigm is a verified supplier
Bioz Manufacturer Symbol fluidigm manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    fluidigm 3160004b
    3160004b, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/Anti-Human+CD39+(A1)-160Gd/pmc13006393-86-9-5
    Average 93 stars, based on 7 article reviews
    3160004b - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    other:

    Article Title: Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial
    Article Snippet: Anti-Human CD39 (A1) 160Gd , Standard BioTools , Cat# 3160004B.

    Article Title: Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells
    Article Snippet: Anti-human CD39 (A1) – 160Gd , Standard Biotools , Cat# 3160004B; RRID: AB_2687648.

    Recombinase Polymerase Amplification:

    Article Title: Spatial dynamics of CD39 + CD8 + exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer
    Article Snippet: The following primary antibodies and detection systems were used for critical IHC assays: PD-L1 antibody (28-8) IHC antigen retrieval and detection panel (Abcam, Clone 28-8, Cat No. ab236676, 1:50), Anti-PD-1 (Abcam, Clone NAT105, Cat No. ab52587, 1:50), AntiCD39 (Abcam, Clone ERP20627, Cat No. ab223842, 1:500), Anti-CD8 (Leica Biosystems, Clone 4B11, Cat No. PA0183, Prediluted), Goat anti-mouse IgG2b CF Dye 647 (Biotium, Polyclonal, Cat No. 20272-1, 1:800), Goat anti-mouse IgG1 CF Dye 488 (Biotium, Polyclonal, Cat No. 20246-1, 1:800), Goat anti-rabbit IgG CF Dye 568 (Biotium, Polyclonal, Cat No. 20103-1, 1:800), EnVision+ Dual Link System-HRP (DAB+) (Agilent Technologies, Cat No. K406311, Prediluted), Anti-CD3 (Agilent Technologies, Clone F7.2.38, Cat No. M7254, 1:20), Anti-CD20cy (Agilent Technologies, Clone L26, Cat No. IS604, Prediluted), and Anti-PNA (Novus, Clone MECA79R, Cat No. NBP2-78792, 1:100). .. The following primary antibodies were used for MC: CD45-106Cd (Fluidigm, Clone HI30, Cat No. 3106001B, 1:100), CD45-110Cd (Fluidigm, Clone HI30, Cat No. 3110001B, 1:100), CD45-111Cd (Fluidigm, Clone HI30, Cat No. 3111001B, 1:100), CD45-112Cd (Fluidigm, Clone HI30, Cat No. 3112001B, 1:100), CD45-113Cd (Fluidigm, Clone HI30, Cat No. 3113001B, 1:100), CD45-114Cd (Fluidigm, Clone HI30, Cat No. 3114001B, 1:100), CCR6-141Pr (Fluidigm, Clone 11A9, Cat No. 3141014A, 1:100), CD45RA-143Nd (Fluidigm, Clone HI100, Cat No. 3143006B, 1:100), CD4-145Nd (Fluidigm, Clone RPA-T4, Cat No. 3145001B, 1:100), CD8-146Nd (Fluidigm, Clone RPA-T8, Cat No. 3146001B, 1:100), Ki67-147Sm (BioLegend, Clone Ki67, Cat No. 350523, 1:100), CD25-149Sm (Fluidigm, Clone 2A3, Cat No. 3149010B, 1:100), OX-40-150Nd (Fluidigm, Clone ACT35, Cat No. 3150023B, 1:100), CD28-152Sm (BioLegend, Clone CD28.2, Cat No. 302937, 1:100), TIM-3-153Eu (Fluidigm, Clone F38-2E2, Cat No. 3153008B, 1:100), CD3-154Sm (Fluidigm, Clone UCHT1, Cat No. 3154003B, 1:100), TOX-155Gd (Miltenyi Biotec, Clone REA473, Cat No. 130-126-455, 1:100), CXCR3-156Gd (Fluidigm, Clone G025H7, Cat No. 3156004B, 1:100), CD27-158Gd (Fluidigm, Clone L128, Cat No. 3158010B, 1:100), FoxP3-159Tb (Fluidigm, Clone 259D/C7, Cat No. 3159028A, 1:100), CD39-160Gd (Fluidigm, Clone A1, Cat No. 3160004B, 1:100), Tbet-161Dy (Fluidigm, Clone 4B10, Cat No. 3161014B, 1:100), CD69-162Dy (Fluidigm, Clone FN50, Cat No. 3162001B, 1:100), CD45RO-164Dy (Fluidigm, Clone UCHL1, Cat No. 3164007B, 1:100), LAG-3-165Ho (Fluidigm, Clone 11C3C65, Cat No. 3165037B, 1:100), CCR7-167Er (Fluidigm, Clone G043H7, Cat No. 3167009A, 1:100), CD127-168Er (Fluidigm, Clone A019D5, Cat No. 3168017B, 1:100), TCF-1-169Tm (BioLegend, Clone 7F11A10, Cat No. 655202, 1:100), CTLA-4-170Er (Fluidigm, Clone 14D3, Cat No. 3170005B, 1:100), CXCR5-171Yb (Fluidigm, Clone RF8B2, Cat No. 3171014B, 1:100), CX3CR1-172Yb (Fluidigm, Clone 2A9-1, Cat No. 3172017B, 1:100), CXCR4-173Yb (Fluidigm, Clone 12G5, Cat No. 3173001B, 1:100), Eomes-174Yb (eBioscience, Clone WD1928, Cat No. 14-4877-82, 1:100), anti-IgG4-175Lu (Southern Biotech, Clone HP6025, Cat No. 9200-01, 1:50). ..



    Similar Products

    cd39 antibody, anti-human  (Miltenyi Biotec)
    93
    Miltenyi Biotec cd39 antibody, anti-human
    Cd39 Antibody, Anti Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/CD39+Antibody%2C+anti-human/custom%40130-125-113%4042526444
    Average 93 stars, based on 1 article reviews
    cd39 antibody, anti-human - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    cd39 entpd1  (Sino Biological)
    94
    Sino Biological cd39 entpd1
    Cd39 Entpd1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/Mouse+CD39+Gene+ORF+cDNA+clone+expression+plasmid%2C+C-HA+tag/pmc13051965-841-0-9
    Average 94 stars, based on 1 article reviews
    cd39 entpd1 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cd39 ax700  (R&D Systems)
    94
    R&D Systems cd39 ax700
    Cd39 Ax700, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/Human+CD39%2FENTPD1+Alexa+Fluor%C2%AE+700-conjugated+Antibody/pm42822324-60-35-37
    Average 94 stars, based on 1 article reviews
    cd39 ax700 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti foxp3 pe  (Miltenyi Biotec)
    93
    Miltenyi Biotec anti foxp3 pe
    Anti Foxp3 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/CD39+Antibody%2C+anti-mouse%2C+REAfinity/pmc13365579-526-72-75
    Average 93 stars, based on 1 article reviews
    anti foxp3 pe - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    ‒ anti cd39 apc  (Miltenyi Biotec)
    93
    Miltenyi Biotec ‒ anti cd39 apc
    ‒ Anti Cd39 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/CD62L+Antibody%2C+anti-mouse%2C+REAfinity/pm42098128-440-70-74
    Average 93 stars, based on 1 article reviews
    ‒ anti cd39 apc - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    anti human cd39 a1 160gd  (fluidigm)
    93
    fluidigm anti human cd39 a1 160gd
    Phenotypic modulation of T cells and enhanced priming by anti-CTLA4-NF (A) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD8 T cells by CyTOF. Clusters were derived from FlowSOM. (B) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (C) Expression of <t>CD39</t> and 4-1BB by geometric MI on CD8 T cells as represented by color mapping on PaCMAP plot. (D) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (E) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD4 + FoxP3 - Tconv cells by CyTOF. Clusters were derived from FlowSOM. (F) Pseudocolor density plots of CD4 Tconv cells in PaCMAP space stratified by treatment group. (G) Expression of CD39 and 4-1BB by geometric MI on CD4 Tconv as represented by color mapping on PaCMAP plot. (H) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD4 Tconv cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. (I) PaCMAP plot of MycCaP-infiltrating CD8 T cells by 45-parameter flow cytometry in response to ADT, ADT + anti-CTLA4 (ND), or ADT + anti-CTLA4 (D). Clusters were derived from FlowSOM. (J) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (K) Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. (L) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. (M) Biaxial plots representing expression of CD44 and Ki67 on CD8 T cells in tumor-draining lymph nodes of mice shown in (I–L). (N) Biaxial plots representing expression of CD44 and Ki67 on CD4 + FoxP3 − Tconv cells in tumor-draining lymph nodes of mice shown in (L–O). (O) Violin plots representing frequencies of CD44 + Ki67 + CD8 and CD4 Tconv cells as a percentage of parent populations stratified by treatment group. Two-tailed Welch’s t test was used to assess statistical significance. All murine data shown are n = 7 per group and representative of two independent experiments each for survival and immune profiling studies.
    Anti Human Cd39 A1 160gd, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/Anti-Human+CD39+(A1)-160Gd/pmc13006393-86-0-5
    Average 93 stars, based on 1 article reviews
    anti human cd39 a1 160gd - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    3160004b  (fluidigm)
    93
    fluidigm 3160004b
    Phenotypic modulation of T cells and enhanced priming by anti-CTLA4-NF (A) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD8 T cells by CyTOF. Clusters were derived from FlowSOM. (B) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (C) Expression of <t>CD39</t> and 4-1BB by geometric MI on CD8 T cells as represented by color mapping on PaCMAP plot. (D) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (E) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD4 + FoxP3 - Tconv cells by CyTOF. Clusters were derived from FlowSOM. (F) Pseudocolor density plots of CD4 Tconv cells in PaCMAP space stratified by treatment group. (G) Expression of CD39 and 4-1BB by geometric MI on CD4 Tconv as represented by color mapping on PaCMAP plot. (H) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD4 Tconv cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. (I) PaCMAP plot of MycCaP-infiltrating CD8 T cells by 45-parameter flow cytometry in response to ADT, ADT + anti-CTLA4 (ND), or ADT + anti-CTLA4 (D). Clusters were derived from FlowSOM. (J) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (K) Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. (L) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. (M) Biaxial plots representing expression of CD44 and Ki67 on CD8 T cells in tumor-draining lymph nodes of mice shown in (I–L). (N) Biaxial plots representing expression of CD44 and Ki67 on CD4 + FoxP3 − Tconv cells in tumor-draining lymph nodes of mice shown in (L–O). (O) Violin plots representing frequencies of CD44 + Ki67 + CD8 and CD4 Tconv cells as a percentage of parent populations stratified by treatment group. Two-tailed Welch’s t test was used to assess statistical significance. All murine data shown are n = 7 per group and representative of two independent experiments each for survival and immune profiling studies.
    3160004b, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/Anti-Human+CD39+(A1)-160Gd/pmc13006393-86-9-5
    Average 93 stars, based on 1 article reviews
    3160004b - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    mouse anti human cd39  (Bio-Rad)
    94
    Bio-Rad mouse anti human cd39
    Phenotypic modulation of T cells and enhanced priming by anti-CTLA4-NF (A) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD8 T cells by CyTOF. Clusters were derived from FlowSOM. (B) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (C) Expression of <t>CD39</t> and 4-1BB by geometric MI on CD8 T cells as represented by color mapping on PaCMAP plot. (D) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (E) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD4 + FoxP3 - Tconv cells by CyTOF. Clusters were derived from FlowSOM. (F) Pseudocolor density plots of CD4 Tconv cells in PaCMAP space stratified by treatment group. (G) Expression of CD39 and 4-1BB by geometric MI on CD4 Tconv as represented by color mapping on PaCMAP plot. (H) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD4 Tconv cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. (I) PaCMAP plot of MycCaP-infiltrating CD8 T cells by 45-parameter flow cytometry in response to ADT, ADT + anti-CTLA4 (ND), or ADT + anti-CTLA4 (D). Clusters were derived from FlowSOM. (J) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (K) Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. (L) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. (M) Biaxial plots representing expression of CD44 and Ki67 on CD8 T cells in tumor-draining lymph nodes of mice shown in (I–L). (N) Biaxial plots representing expression of CD44 and Ki67 on CD4 + FoxP3 − Tconv cells in tumor-draining lymph nodes of mice shown in (L–O). (O) Violin plots representing frequencies of CD44 + Ki67 + CD8 and CD4 Tconv cells as a percentage of parent populations stratified by treatment group. Two-tailed Welch’s t test was used to assess statistical significance. All murine data shown are n = 7 per group and representative of two independent experiments each for survival and immune profiling studies.
    Mouse Anti Human Cd39, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/Mouse+anti+Human+CD39/us12569592-1790-3-8
    Average 94 stars, based on 1 article reviews
    mouse anti human cd39 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    biotinylated anti mouse cd39 antibody  (Miltenyi Biotec)
    93
    Miltenyi Biotec biotinylated anti mouse cd39 antibody
    Phenotypic modulation of T cells and enhanced priming by anti-CTLA4-NF (A) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD8 T cells by CyTOF. Clusters were derived from FlowSOM. (B) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (C) Expression of <t>CD39</t> and 4-1BB by geometric MI on CD8 T cells as represented by color mapping on PaCMAP plot. (D) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (E) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD4 + FoxP3 - Tconv cells by CyTOF. Clusters were derived from FlowSOM. (F) Pseudocolor density plots of CD4 Tconv cells in PaCMAP space stratified by treatment group. (G) Expression of CD39 and 4-1BB by geometric MI on CD4 Tconv as represented by color mapping on PaCMAP plot. (H) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD4 Tconv cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. (I) PaCMAP plot of MycCaP-infiltrating CD8 T cells by 45-parameter flow cytometry in response to ADT, ADT + anti-CTLA4 (ND), or ADT + anti-CTLA4 (D). Clusters were derived from FlowSOM. (J) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (K) Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. (L) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. (M) Biaxial plots representing expression of CD44 and Ki67 on CD8 T cells in tumor-draining lymph nodes of mice shown in (I–L). (N) Biaxial plots representing expression of CD44 and Ki67 on CD4 + FoxP3 − Tconv cells in tumor-draining lymph nodes of mice shown in (L–O). (O) Violin plots representing frequencies of CD44 + Ki67 + CD8 and CD4 Tconv cells as a percentage of parent populations stratified by treatment group. Two-tailed Welch’s t test was used to assess statistical significance. All murine data shown are n = 7 per group and representative of two independent experiments each for survival and immune profiling studies.
    Biotinylated Anti Mouse Cd39 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/CD39+Antibody%2C+anti-mouse%2C+REAfinity/pm41216948-48-13-20
    Average 93 stars, based on 1 article reviews
    biotinylated anti mouse cd39 antibody - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    anti cd39  (Novus Biologicals)
    94
    Novus Biologicals anti cd39
    Phenotypic modulation of T cells and enhanced priming by anti-CTLA4-NF (A) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD8 T cells by CyTOF. Clusters were derived from FlowSOM. (B) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (C) Expression of <t>CD39</t> and 4-1BB by geometric MI on CD8 T cells as represented by color mapping on PaCMAP plot. (D) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (E) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD4 + FoxP3 - Tconv cells by CyTOF. Clusters were derived from FlowSOM. (F) Pseudocolor density plots of CD4 Tconv cells in PaCMAP space stratified by treatment group. (G) Expression of CD39 and 4-1BB by geometric MI on CD4 Tconv as represented by color mapping on PaCMAP plot. (H) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD4 Tconv cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. (I) PaCMAP plot of MycCaP-infiltrating CD8 T cells by 45-parameter flow cytometry in response to ADT, ADT + anti-CTLA4 (ND), or ADT + anti-CTLA4 (D). Clusters were derived from FlowSOM. (J) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (K) Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. (L) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. (M) Biaxial plots representing expression of CD44 and Ki67 on CD8 T cells in tumor-draining lymph nodes of mice shown in (I–L). (N) Biaxial plots representing expression of CD44 and Ki67 on CD4 + FoxP3 − Tconv cells in tumor-draining lymph nodes of mice shown in (L–O). (O) Violin plots representing frequencies of CD44 + Ki67 + CD8 and CD4 Tconv cells as a percentage of parent populations stratified by treatment group. Two-tailed Welch’s t test was used to assess statistical significance. All murine data shown are n = 7 per group and representative of two independent experiments each for survival and immune profiling studies.
    Anti Cd39, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd39/CD39%2FENTPD1+Antibody+(17B5F11)+-+BSA+Free/pmc12932206-80-8-9
    Average 94 stars, based on 1 article reviews
    anti cd39 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Phenotypic modulation of T cells and enhanced priming by anti-CTLA4-NF (A) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD8 T cells by CyTOF. Clusters were derived from FlowSOM. (B) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (C) Expression of CD39 and 4-1BB by geometric MI on CD8 T cells as represented by color mapping on PaCMAP plot. (D) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (E) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD4 + FoxP3 - Tconv cells by CyTOF. Clusters were derived from FlowSOM. (F) Pseudocolor density plots of CD4 Tconv cells in PaCMAP space stratified by treatment group. (G) Expression of CD39 and 4-1BB by geometric MI on CD4 Tconv as represented by color mapping on PaCMAP plot. (H) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD4 Tconv cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. (I) PaCMAP plot of MycCaP-infiltrating CD8 T cells by 45-parameter flow cytometry in response to ADT, ADT + anti-CTLA4 (ND), or ADT + anti-CTLA4 (D). Clusters were derived from FlowSOM. (J) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (K) Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. (L) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. (M) Biaxial plots representing expression of CD44 and Ki67 on CD8 T cells in tumor-draining lymph nodes of mice shown in (I–L). (N) Biaxial plots representing expression of CD44 and Ki67 on CD4 + FoxP3 − Tconv cells in tumor-draining lymph nodes of mice shown in (L–O). (O) Violin plots representing frequencies of CD44 + Ki67 + CD8 and CD4 Tconv cells as a percentage of parent populations stratified by treatment group. Two-tailed Welch’s t test was used to assess statistical significance. All murine data shown are n = 7 per group and representative of two independent experiments each for survival and immune profiling studies.

    Journal: Cell Reports Medicine

    Article Title: Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial

    doi: 10.1016/j.xcrm.2026.102638

    Figure Lengend Snippet: Phenotypic modulation of T cells and enhanced priming by anti-CTLA4-NF (A) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD8 T cells by CyTOF. Clusters were derived from FlowSOM. (B) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (C) Expression of CD39 and 4-1BB by geometric MI on CD8 T cells as represented by color mapping on PaCMAP plot. (D) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (E) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD4 + FoxP3 - Tconv cells by CyTOF. Clusters were derived from FlowSOM. (F) Pseudocolor density plots of CD4 Tconv cells in PaCMAP space stratified by treatment group. (G) Expression of CD39 and 4-1BB by geometric MI on CD4 Tconv as represented by color mapping on PaCMAP plot. (H) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD4 Tconv cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. (I) PaCMAP plot of MycCaP-infiltrating CD8 T cells by 45-parameter flow cytometry in response to ADT, ADT + anti-CTLA4 (ND), or ADT + anti-CTLA4 (D). Clusters were derived from FlowSOM. (J) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (K) Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. (L) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. (M) Biaxial plots representing expression of CD44 and Ki67 on CD8 T cells in tumor-draining lymph nodes of mice shown in (I–L). (N) Biaxial plots representing expression of CD44 and Ki67 on CD4 + FoxP3 − Tconv cells in tumor-draining lymph nodes of mice shown in (L–O). (O) Violin plots representing frequencies of CD44 + Ki67 + CD8 and CD4 Tconv cells as a percentage of parent populations stratified by treatment group. Two-tailed Welch’s t test was used to assess statistical significance. All murine data shown are n = 7 per group and representative of two independent experiments each for survival and immune profiling studies.

    Article Snippet: Anti-Human CD39 (A1) 160Gd , Standard BioTools , Cat# 3160004B.

    Techniques: Derivative Assay, Expressing, Flow Cytometry, Two Tailed Test